New targeted agent produces considerable responses in patients with uterine cancer

The DNA repair-blocking drug adavosertib shrinks tumors in nearly one-third of patients in clinical trial data to be shared at the Society for Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer.

from Women's Health News -- ScienceDaily https://ift.tt/2zuL8VV